ANI Pharmaceuticals (ANIP) SVP reports tax-withholding share disposition

Rhea-AI Filing Summary

ANI Pharmaceuticals SVP Krista Davis reported a tax-withholding share disposition. On February 11, 2026, 3,017 shares of ANI Pharmaceuticals common stock were disposed of at $76.25 per share as a tax-withholding disposition related to equity compensation.

The footnote explains that these shares were withheld for tax purposes in connection with the vesting of 8,104 performance stock units, a grant originally reported on April 6, 2023. After this transaction, Davis directly owned 55,547 shares of ANI Pharmaceuticals common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Davis Krista

(Last) (First) (Middle)

C/O ANI PHARMACEUTICALS, INC.

210 MAIN STREET WEST

(Street)

BAUDETTE MN 56623

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, CHIEF HR OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
02/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/11/2026		F(1)		3,017	D	$76.25	55,547	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 8,104 performance stock units, the grant of which was previously reported on April 6, 2023.

Remarks:

	/s/ Krista Davis, by attorney-in-fact Meredith W. Cook	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ANIP executive Krista Davis report on this Form 4?

Krista Davis reported a tax-withholding share disposition. On February 11, 2026, 3,017 shares of ANI Pharmaceuticals common stock were disposed of at $76.25 per share to cover tax obligations linked to vesting performance stock units.

How many ANIP shares were involved in Krista Davis’s February 11, 2026 transaction?

The transaction involved 3,017 common shares. These shares were disposed of at $76.25 per share as part of a tax-withholding disposition connected to the vesting of previously granted performance stock units.

How many ANI Pharmaceuticals (ANIP) shares does Krista Davis own after this Form 4 transaction?

Krista Davis directly owns 55,547 ANIP shares after the transaction. This post-transaction balance reflects the impact of 3,017 shares withheld for taxes in connection with the vesting of performance stock units.

What does the footnote on Krista Davis’s ANIP Form 4 transaction explain?

The footnote explains the shares were withheld for taxes. It states the disposition is exempt under Rule 16(b)-3 and tied to the vesting of 8,104 performance stock units originally reported on April 6, 2023.

Was Krista Davis’s ANIP Form 4 transaction an open-market sale of shares?

No, it was a tax-withholding disposition. The code F and footnote indicate shares were withheld for tax purposes under Rule 16(b)-3 in connection with vesting performance stock units, rather than an ordinary open-market sale.

What role does Krista Davis hold at ANI Pharmaceuticals (ANIP)?

Krista Davis serves as SVP, Chief HR Officer at ANIP. The Form 4 identifies her as an officer of ANI Pharmaceuticals, reporting this equity-related tax-withholding transaction as required under Section 16 rules.